- Trials with a EudraCT protocol (903)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
903 result(s) found for: Cell Suspension.
Displaying page 1 of 46.
EudraCT Number: 2021-001351-13 | Sponsor Protocol Number: APHP201133 | Start Date*: 2021-11-26 | |||||||||||
Sponsor Name:Assistance Publique des Hôpitaux de Paris(AP-HP) | |||||||||||||
Full Title: Interest of famotidine in reducing endothelial expression of P-selectin in children with sickle cell disease: pilot study, single-center, prospective, non-comparative | |||||||||||||
Medical condition: major sickle cell syndrome | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002524-42 | Sponsor Protocol Number: FM-DLBCL06-01 | Start Date*: 2006-09-20 | |||||||||||
Sponsor Name:FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI | |||||||||||||
Full Title: Use of mieloablative doses of zevalin in aggressive lymphomas of the elderly. Prospective randomized study Z-HDS1,2 vs R-CHOP | |||||||||||||
Medical condition: Aggressive malignant lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000573-20 | Sponsor Protocol Number: 1.0 | Start Date*: 2016-06-14 |
Sponsor Name:Department of Sports Medicine, Institute for Sport Sciences, Justu-Liebig-University of Gießen | ||
Full Title: Effects of MUTAFLOR® on exercise-induced gastro-intestinal dysfunction | ||
Medical condition: To investigate the effects of Mutaflor® Suspension on exercise induced gastrointestinal symptoms for 3 hours after a strenous exercise test on a treadmill | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-000720-13 | Sponsor Protocol Number: TSU-2/CDA | Start Date*: 2010-10-27 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, randomised, placebo-controlled, multi-centre phase II study to evaluate the efficacy and safety of three different dosages of oral Trichuris suis ova (TSO) suspension in active Crohn’... | |||||||||||||
Medical condition: Induction of remission in active Crohn´s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) DK (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000454-44 | Sponsor Protocol Number: R-C5R 2006 | Start Date*: 2007-05-23 | |||||||||||
Sponsor Name:Groupe d’Etude des Lymphomes de l’Adulte (GELA) | |||||||||||||
Full Title: Etude prospective multicentrique de phase II évaluant l’adjonction du rituximab et du DepoCyte® en intrathécal au protocole de chimiothérapie C5R chez les patients âgés de 18 à 60 ans porteurs de l... | |||||||||||||
Medical condition: Patiens with primary cerebral or oculocerebral NHL not previously treated with chemotherapy or radiotherapy and diffuse large B-cell lymphomas, with cerebral and / or neuromeningeal involvement at ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003668-32 | Sponsor Protocol Number: 2019-BN-001 | Start Date*: 2019-12-18 | ||||||||||||||||||||||||||
Sponsor Name:UZ Brussel | ||||||||||||||||||||||||||||
Full Title: A randomized phase II clinical trial of SBRT and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/ CD141 (BDCA-3)+ myeloid dendritic cells in NSCLC | ||||||||||||||||||||||||||||
Medical condition: Oligometastatic solid tumors. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001006-18 | Sponsor Protocol Number: D5136C00007 | Start Date*: 2014-08-27 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: Multicenter, open-label, randomised, pharmacokinetic (PK) and pharmacodynamic (PD) dose-ranging Phase II study of ticagrelor followed by a double-blind, randomised, parallel-group, placebo-controll... | |||||||||||||
Medical condition: Investigation of platelet aggregation in paediatric patients with sickle cell disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003641-14 | Sponsor Protocol Number: D5136C00010 | Start Date*: 2018-01-29 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multi-centre, Phase I, Open-label, Single-dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to less than 24 Months, with Sickle Cell Disease | |||||||||||||
Medical condition: Sickle Cell Disease | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012412-41 | Sponsor Protocol Number: IFCT-0803 | Start Date*: 2010-01-11 | |||||||||||
Sponsor Name:IFCT | |||||||||||||
Full Title: Etude de phase II évaluant l’association de cetuximab à une radiothérapie et chimiothérapie concomitante par cisplatine et pemetrexed dans le traitement des cancers bronchiques non à petites cellul... | |||||||||||||
Medical condition: Stage III Non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004521-28 | Sponsor Protocol Number: HHSC/010 | Start Date*: 2009-06-30 |
Sponsor Name:Imperial College London | ||
Full Title: A multi-centre phase I/II safety and tolerability study following the infusion of expanded autologous progeny of an adult CD34 positive stem cell subset to patients with recent tibial fractures. | ||
Medical condition: Fractured Tibia | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000903-26 | Sponsor Protocol Number: GBT440-032 | Start Date*: 2022-02-02 | |||||||||||
Sponsor Name:Global Blood Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease (HOPE Kids 2) | |||||||||||||
Medical condition: Sickle Cell Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001623-18 | Sponsor Protocol Number: EGF102988 | Start Date*: 2006-12-07 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or P... | |||||||||||||
Medical condition: Resected Squamous Cell Carcinoma of the Head and Neck | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) IE (Completed) GR (Completed) AT (Completed) SK (Completed) GB (Completed) DE (Completed) CZ (Completed) PT (Prematurely Ended) EE (Completed) HU (Completed) IT (Completed) LV (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001397-15 | Sponsor Protocol Number: BMMNC_CLI_001 | Start Date*: 2016-06-15 | |||||||||||
Sponsor Name:Institut klinické a experimentální medicíny | |||||||||||||
Full Title: A prospective, randomized study to compare the effect on tissue oxygenation and clinical outcome of autologous bone marrow-derived mononuclear cell therapy with standard treatment in patients with ... | |||||||||||||
Medical condition: Autologous cell therapy (ACT) is new technique for patients with critical limb ischemia and diabetic foot (DF). In our study, the effect of ACT and also the repetitive treatment will be compared wi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000526-21 | Sponsor Protocol Number: VINST | Start Date*: 2012-05-07 | |||||||||||
Sponsor Name:Västra Götalandregionen (VGR) [...] | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002867-13 | Sponsor Protocol Number: POP6135,HMR3647B/3005 | Start Date*: 2015-03-17 | |||||||||||
Sponsor Name:Sanofi-aventis | |||||||||||||
Full Title: Multinational, randomized, double blind, double dummy, pharmacokinetic study of telithromycin oral suspension (25 mg/kg once daily for 7-10 days), with secondary assessments of safety relative to a... | |||||||||||||
Medical condition: Community acquired pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003060-20 | Sponsor Protocol Number: CCTL019C2201 | Start Date*: 2015-10-06 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) | ||||||||||||||||||
Medical condition: Adult patients ≥ 18 years with relapsed or refractory DLBCL, having failed 2 or more lines of therapy and not eligible for HSCT | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) DE (Completed) NO (Completed) NL (Ongoing) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001398-34 | Sponsor Protocol Number: BMMNC_PTA_001 | Start Date*: 2016-06-15 | |||||||||||
Sponsor Name:Institut klinické a experimentální medicíny | |||||||||||||
Full Title: A prospective, randomized study to assess the effect of autologous bone marrow-derived mononuclear cell therapy and its combination with percutaneous transluminal angioplasty (PTA) in comparison wi... | |||||||||||||
Medical condition: In our study, the effect of autologous cell therapy (ACT) will be compared with repeated percutaneous transluminal angioplasty (re-PTA) in patients with diabetic foot and then will be compared the ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003572-23 | Sponsor Protocol Number: GCP#01.01.030 | Start Date*: 2017-12-27 | ||||||||||||||||
Sponsor Name:Gamida Cell Ltd | ||||||||||||||||||
Full Title: Allogeneic Stem Cell Transplantation of CordIn™, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients with Hemoglobinopathies | ||||||||||||||||||
Medical condition: Hemoglobinopathies | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-003137-32 | Sponsor Protocol Number: ITMO 002 | Start Date*: 2006-09-26 | |||||||||||
Sponsor Name:I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY | |||||||||||||
Full Title: A randomized, open label, multicenter phase II study of first line therapy with Sorafenib in association with Interleukin 2 versus Sorafenib alone in patients with unresectable and/or metastatic re... | |||||||||||||
Medical condition: ADVANCED RENAL CELL CANCER | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002556-41 | Sponsor Protocol Number: TRX 1.0 | Start Date*: 2008-02-07 | |||||||||||
Sponsor Name:Trimed Biotech GmbH | |||||||||||||
Full Title: A randomized, open-label, 2-arm, multicentre, Phase II study to evaluate the safety and efficacy of Trivax, a dendritic cell-based interleukin-12 secreting autologous cancer vaccine, in combination... | |||||||||||||
Medical condition: Metastatic renal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.